Abbott (Switzerland)

Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis

Abstract Introduction Biologic treatments demonstrate long-term clinical benefits for patients with osteoporosis, but their cost is prohibitive, and access can be limited, particularly in low-income countries. This analysis determined the cost impact of introducing biosimilar den...